Glycomimetics, Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
8
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Methods for treating acute myeloid leukemia and related conditions (US 11,707,474) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 2 fees due Feb 1 to 18, 2027 · next Feb 1
- 1 fee due Apr 10, 2027The maintenance fee for Highly potent multimeric e-selectin antagonists (US 11,780,873) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Heterobifunctional inhibitors of E-selectin and galectin-3 (US 11,845,771) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 3 fees due Jul 7 to 23, 2027 · next Jul 7
Recent changes
- 2 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,517,980 | Glycomimetric inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas In force · From the USPTO record | In force | From the USPTO record | |
| US 8,258,290 | Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from pseudomonas In force · From the USPTO record | In force | From the USPTO record | |
| US 8,361,975 | Compounds and methods for treatment of sickle cell or complications associated therewith In force · From the USPTO record | In force | From the USPTO record | |
| US RE44,778 | Heterobifunctional pan-selectin inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,534,009 | Pan-selectin inhibitor with enhanced pharmacokinetic activity In force · From the USPTO record | In force | From the USPTO record | |
| US 8,039,442 | Compounds and methods for treatment of sickle cell disease or complications associated therewith In force · From the USPTO record | In force | From the USPTO record | |
| US 7,964,569 | Glycomimetic replacements for hexoses and N-acetyl hexosamines In force · From the USPTO record | In force | From the USPTO record | |
| US 8,026,222 | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines In force · From the USPTO record | In force | From the USPTO record | |
| US 8,921,328 | E-Selectin Antagonists In force · High confidence | In force | High confidence | |
| US 8,895,510 | Pan-selectin inhibitor with enhanced pharmacokinetic activity In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 24: 2 patents in force now held by others · 11 lapsed for an unpaid fee · 13 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 4 abandoned · 42 no status recorded